Member Info for risehall1

Yeah yeah on to £19.15 and then £54. I wouldn't mind if it did happen but I reckon there is better odds on winning the lottery. One blue day in a sea of red does not necessarily mean things have turned.

I don't think there is any anti French sentiment in the UK. Brexit was more about regaining control of borders and immigration than anything else. The perception here is that Europe wants to punish the UK for leaving and a lot of what Macron does and says is intended for a domestic audience.

Yes, there are pre action protocols for commercial disputes and arbitration/negotiation doesn't usually take this long. Even if they had to obtain expert evidence on say, whether the product supplied was of a satisfactory quality, you would expect that to have been done by now and a settlement achieved. Nearly all commercial disputes settle out of Court. Neither party has issued Court proceedings. That makes me think as with Abingdon the DHSC are wanting to await the outcome of the GLP hearing to determine whether the contract is legal. If court proceedings are issued it all goes into the public domain, one huge mess.

At the present time I doubt a shareholder revolt would be helpful to shareholder interests. All the problems this year flow from the actions of the DHSC. They have cancelled contracts, refused to pay for goods they purchased, are the subject of judicial review proceedings, and are now delaying product approvals. It is not just Novacyt affected. Better to complain to the DHSC and tell them you are complaining to your MP. I am surprised the DHSC haven't just paid the outstanding contracts. This is going to come back and bite them because rather than people quietly forgetting about the whole cash for contracts saga, it has the potential to blow up big time in December.

Dont forget that £100m is net of writedowns and they are owed £78m by DHSC.

Whoever wrote that absolutely nailed it. Though to be fair on Novacyt, the teething troubles have a lot to do with having grown rapidly in s short space of time.

https://www.dailymail.co.uk/news/article-10174647/Elderly-double-jabbed-started-dying-Covid-waning-immunity.html

If it has been tested on mice and doesn't kill them then it must be safe for humans. But if it gives the mice cancer that doesn't mean it will cause cancer in humans.

Very little non covid revenue and to further complicate matters as to future revenue a lot of the non covid revenue has been reduced by covid. But remember that was back in the days when Novacyt struggled to raise capital, couldn't afford stock - including machines (huge barrier to growth!!) and was struggling to service a big pile of debt. The covid revenue isn't going to suddenly dry up which will serve as a cushion to diversify, the debts are paid off, there is cash in the bank, there is a huge sales network in place, there is the ability and expertise to develop and make tests, testing machines and reagants. Perhaps the greatest thing going in Nova's favour has been how quick they moved at the outset and how they have turned that into profits. The DHSC has been a complete **** up, but that will be settled at some point.

Just seen this report on a mutation which was detected some time ago. Is it just now a matter of time before vaccines need to be reformulated to remain effective?
https://www.nature.com/articles/s41423-021-00779-5

Primerdesign is dark purple on the pie chart. It was mentioned the half yearly results that long term supply agreements had been made with WHO and Unicef. This might well explain the gift of 1 million free tests. The price though, without evidence I wouldn't assume $7 per test. There may be a hefty discount for a large contract. It is good because it will certainly run into 2022 and perhaps beyond, but also it is a good selling point to other customers. Carries some prestige to be supplier to WHO and Unicef.

Cases rising in France too https://www.reuters.com/world/europe/france-reports-more-than-10000-new-covid-cases-1st-time-two-months-2021-11-03/

But Novacyt now has no debt, has the ability to develop new products in house, has now built a massive ssles network both in the UK and globally, has numerous machines in use, is now a manufacturer of testing machines and reagants in addition to tests, cash reserves equivalent to £1+ a share, growing demand for testing regardless of covid. They say never try to catch a falling knife, but there has to be a bottom somewhere. Settle the DHSC dispute and this should soar.

Just look at the new normal - winter 2021, across Northern Europe as weather gets cold and damp cases now rising sharply in Denmark, Holland, Belgium, Germany, Poland. This is with vaccines. Hospitals and healthcare struggling to cope. Shortages of intensive care beds, rising deaths. In the UK, Delta Plus is set to become the dominant strain by January. It is at least 10% more infectious than Delta. So aside from the **** up by DHSC, demand for testing is robust and will continue to be so for some time yet. I can't see this ending in 2022. The virus is still mutating, vaccines are not 100% and wear off over time

I don't see anything better about it and expect their share price will fall by just as much as AVCT and NYCT, if not more. I don't think this was a deliberate attempt by the DHSC to destroy the UK diagnostics industry just complete incompetence. They haven't allowed sufficient time to assess tests nor considered the consequences of failing to do so. As usual those responsible will have no consequences for themselves and won't be disciplined.

This is not just an issue affecting Novacyt. Actually it puts the existing DHSC dispute in perspective. We have an incompetent government and an incompetent civil service. As I have gotten older, I have come to realise this country is in a state of accelerating decline.

The AVCT gave some useful background information though in that only three reviews have actually been completed. So it is the fault of the UK government. But it is bad for Novacyt because if you cannot sell your product, you lose customers.

With respect your comments don't make sense. Novacyt haven't been paid for much of the disputed goods so how can DHSC claim the value of the contracted goods? We were told by Novacyt that at worst they consider this to be a warranty claim. Under English Law there are quite strict limitations on what can be claimed for breach of contract including the requirement to mitigate your losses and difficulty claiming consequential losses, e.g. if DHSC were arguing they incurred expense buying the same goods from an alternative supplier.

For the fifth time too. Maybe he's a super spreader.

Tightening it's zero covid strategy, building massive isolation centres, expanding vacination to children as young as 3 and restricting entry via their borders. Strange that the Chinese are adopting these different approaches to something we in the West are happy to let spread and mutate. You would almost think that a biological weapon had been accidentally released from a military lab and they were worried about it mutating into something nastier. https://www.google.com/amp/s/www.aljazeera.com/amp/news/2021/10/27/china-doubles-down-on-covid-zero-strategy